Effect of Neo-Adjuvant Chemotherapy On Estrogen Receptor (ER), Progesterone (PR) Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), And Ki-67 Index in Breast Carcinoma
DOI:
https://doi.org/10.51253/pafmj.v76iSUPPL-8.9506Keywords:
Estrogen Receptor, HER2, Invasive Breast Carcinoma, Ki-67 Index, Neo-Adjuvant Chemotherapy, Progesterone Receptor.Abstract
Objective: To know the outcome of neo-adjuvant therapy on hormone receptors, HER2, and Ki-67 index in invasive breast carcinoma.
Study Design: Prospective analytical study
Place and Duration of Study: Histopathology department, Armed Forces Institute of Pathology, Rawalpindi, Pakistan, from Dec 21 to Oct 22.
Methodology: We included 110 patients with histologically proven invasive breast carcinoma in our study. Rate of expression of ER, PR, HER2, and Ki-67 index was assessed in pre-neoadjuvant needle-core specimens, followed by administration of neo-adjuvant chemotherapy, and then the receptor statuses were evaluated on surgically excised specimens of the same patients. A paired t-test was applied to analyse the changes in receptor expression.
Results: Among 110 patients, the average age was 48.47±10.12 years. The most common histological type was invasive ductal carcinoma, no special type noted in 97 (88.2%), and the most common histological grade was II, noted in 66 (60%). Discordance of ER is noted in 34 (30.91%) cases, and for PR in 29 (26.37%) cases. Overall, HER2 receptor negativity increased from 41 (37.30%) to 51 (46.40%) cases. The average Ki-67 index decreased from 27.34% to 24.03% after administration of chemotherapy.
Conclusion: Neo-adjuvant chemotherapy administration may cause changes in receptor expression, mainly in ER and Ki-67 index. These findings are helpful in the choice of sequential adjuvant therapy and improve treatment and prognosis in invasive breast carcinoma.
Downloads
References
1. Zaheer S, Shah N, Maqbool SA, Soomro NM. Estimates of past and future time trends in age-specific breast cancer incidence among women in Karachi, Pakistan: 2004–2025. BMC Public Health 2019; 19(1): 1-9.
https://doi.org/10.1186/s12889-019-7330-z
2. Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast cancer 2020;14:1178223420980377.
https://doi.org/10.1177/1178223420980377
3. Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018; 19(1): 27-39. https://doi.org/10.1016/S1470-2045(17)30777-5
4. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014;2014: 2014: 852748. https://doi.org/10.1155/2014/852748
5. Giuliano M, Hu H, Wang Y-C, Fu X, Nardone A, Herrera S, et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res 2015; 21(17): 3995-4003.
https://doi.org/10.1158/1078-0432.ccr-14-2728
6. Badowska-Kozakiewicz AM, Patera J, Sobol M, Przybylski J. The role of oestrogen and progesterone receptors in breast cancer–immunohistochemical evaluation of oestrogen and progesterone receptor expression in invasive breast cancer in women. Contemp Oncol 2015; 19(3): 220-225. https://doi.org/10.5114/wo.2015.51826
7. Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther 2022; 16: 305-314. https://doi.org/10.2147/dddt.s336643
8. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-249.
https://doi.org/10.3322/caac.21660
9. Mansoor H, Waqar E, Tariq R. Prevalence of vitamin D deficiency in Pakistani females and its link to breast cancer. JPMA 2022; 72(01): 202.
https://doi.org/10.47391/JPMA.11-4169
10. Ramteke P, Seenu V, Prashad R, Gupta S, Iyer V, Deo S, et al. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India. Indian J Cancer 2016; 53(3): 366-371.
https://doi.org/10.4103/0019-509x.200669
11. Peng J-H, Zhang X, Song J-L, Ran L, Luo R, Li H-Y, et al. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 in invasive ductal carcinoma. Medicine 2019; 98(2): e13554.
https://doi.org/10.1097/md.0000000000013554
12. Verma A, Kar AG, Meena RN, et al. Evaluation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status before and after neoadjuvant chemotherapy in breast cancer patients. Indian J Surg 2021; 83(Suppl 2): 399‑403. https://doi:10.1007/s12262‑020‑02380‑y.
13. Berna J, Michel S, Bouazzi L, et al. Predictive factors for breast‑conserving surgery after neoadjuvant chemotherapy in breast cancer. World J Surg Oncol 2025; 23: 425. https://doi:10.1186/s12957‑025‑03820‑3.
14. Abu El‑Ela RY, Hassan M, Kholosy RM . A multicenter retrospective study of neoadjuvant chemotherapy and breast conservation rate in locally advanced breast cancer. Discov Onc 2026; 17: 549.https://doi.org/10.1007/s12672-026-04738-2
15. Zhu XJ, Zhang H, Zhang S, Li D, Li X, Xu L, Li T. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression. Beijing Da Xue Xue Bao Yi Xue Ban 2023; 55(2): 243-253. https://doi:10.19723/j.issn.1671-167X.2023.02.007.
16. Roskoski R Jr. Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharmacol Res 2024; 210: 107534. https://doi:10.1016/j.phrs.2024.107534.
17. Hu X, Chen W, Li F, Ren P, Wu H, Zhang C, Gu K. Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance. Front Oncol 2023; 13: 1053125. https://doi:10.3389/fonc.2023.1053125.
18. Kawsar H, Sinha A, Ali M, Phukan J, Pathak S. Histopathological evaluation of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor‑2/Neu expressions in breast carcinoma and their correlations with other prognostic factors: a hospital‑based study. J Med Sci 2022; 42: 221‑227. https://doi:10.4103/jmedsci.jmedsci_245_21.
19. Peng L, Zhang Z, Zhao D, Zhao J, Mao F, Sun Q. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early-Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases. Pathol Oncol Res ; 27: 599894. https://doi:10.3389/pore.2021.599894.
20. Badr NM, Zaakouk M, Zhang Q, Kearns D, Kong A, Shaaban AM. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist. Histopathol 2024; 85(3): 437-450. https://doi:10.1111/his.15193.
21. Schettini F, Saracchini S, Bassini A, Marus W, Corsetti S, Specogna I, et al. Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study. Breast 2024; 76: 103753. https://doi:10.1016/j.breast.2024.103753.
22. de Mooij CM, Ploumen RAW, Nelemans PJ, Mottaghy FM, Smidt ML, van Nijnatten TJA. The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in https://doi:10.1186/s13550-023-00953-y.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Wajahat Ahmed Khan, Muhammad Asif, Hafeez Ud Din, Nadeem Zafar, Farhat Rashid, Hassan Tariq, Umair Aslam
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
